Targeting specific gene fusions in salivary gland cancer with a new drug
Targeting oncogenic Myb fusions in salivary gland cancer with the elongation inhibitor SVC112
This study is looking at two types of salivary gland cancer to see how a new drug called SVC112 can help slow down tumor growth and find better treatment options for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project ID | NIH-11054636 on NIH RePORTER |
What this research studies
This research focuses on salivary gland cancer, particularly adenoid cystic carcinoma and mucoepidermoid carcinoma, which currently lack approved targeted therapies. The team has developed a large bank of patient-derived xenograft (PDX) models to study these cancers and their genetic mutations. They aim to explore the effects of a drug called SVC112, which inhibits protein synthesis, on cancer cells. By understanding how this drug affects tumor growth and gene expression, the research seeks to identify new treatment options for patients with these rare cancers.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with adenoid cystic carcinoma or mucoepidermoid carcinoma of the salivary glands.
Not a fit: Patients with other types of salivary gland cancers or those who do not have oncogenic Myb fusions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new targeted therapies for patients suffering from salivary gland cancer.
How similar studies have performed: While targeting protein synthesis in cancer is a novel approach, preliminary studies have shown promise in other cancer types, suggesting potential for success in this area.
Where this research is happening
Aurora, UNITED STATES
- University of Colorado Denver — Aurora, United States (Active)
Researchers
- Principal investigator: Jimeno, Antonio — University of Colorado Denver
- Study coordinator: Jimeno, Antonio
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.